46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00931086 (ClinicalTrials.gov)	April 2009	30/6/2009	Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99	An Expanded Access Trial of Belimumab Antibody (Monoclonal Anti-BLyS Antibody) in Patients With Rheumatoid Arthritis (RA) Who Were Previously Treated Under HGS Protocol LBRA99	Rheumatoid Arthritis	Drug: belimumab	Human Genome Sciences Inc., a GSK Company	GlaxoSmithKline	No longer available	18 Years	N/A	Both		Phase 4	United States
2	NCT00583557 (ClinicalTrials.gov)	January 2005	20/12/2007	A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01	A Multi-Center, Open-Label, Continuation Trial of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) Who Completed the Phase 2 Protocol LBRA01	Rheumatoid Arthritis	Drug: belimumab	Human Genome Sciences Inc.	NULL	Terminated	18 Years	N/A	All	155	Phase 2	United States;Poland
3	NCT00071812 (ClinicalTrials.gov)	December 2003	31/10/2003	A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)	A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: Placebo;Drug: Belimumab 1 mg/kg;Drug: Belimumab 4 mg/kg;Drug: Belimumab 10 mg/kg	Human Genome Sciences Inc.	NULL	Completed	18 Years	65 Years	All	283	Phase 2	United States